editas
medicine
announces
patent
trademark
office
grants
broad
institute
priority
benefit
crispr
interference
cambridge
globe
newswire
editas
medicine
nasdaq
edit
leading
genome
editing
company
announced
today
patent
trademark
office
uspto
issued
decision
interference
university
california
university
vienna
emmanuelle
charpentier
cvc
broad
institute
broad
regarding
certain
broad
crispr
patents
editas
medicine
exclusively
licenses
uspto
granted
broad
motion
priority
benefit
denying
cvc
priority
benefit
two
earliest
provisional
patent
applications
result
broad
enter
priority
phase
interference
senior
party
cvc
remains
junior
party
purposes
determining
entity
first
invent
inventions
issue
pleased
patent
trademark
office
decision
granting
broad
motion
priority
benefit
look
forward
proceedings
remain
confident
foundational
patent
portfolio
broad
institute
proceedings
ongoing
take
time
believe
outcome
ultimately
positive
broad
institute
innovative
fundamental
work
crispr
gene
editing
said
cynthia
collins
president
chief
executive
officer
editas
medicine
broad
patents
continue
valid
force
foundational
claims
covering
use
crispr
gene
editing
eukaryotic
cells
also
issued
broad
patents
united
states
australia
europe
japan
china
jurisdictions
editas
medicine
leading
genome
editing
company
editas
medicine
focused
translating
power
potential
crispr
crispr
also
known
genome
editing
systems
robust
pipeline
treatments
people
living
serious
diseases
around
world
editas
medicine
aims
discover
develop
manufacture
commercialize
transformative
durable
precision
genomic
medicines
broad
class
diseases
latest
information
scientific
presentations
please
visit
statements
press
release
contains
statements
information
within
meaning
private
securities
litigation
reform
act
words
anticipate
believe
continue
could
estimate
expect
intend
may
plan
potential
predict
project
target
would
similar
expressions
intended
identify
statements
although
statements
contain
identifying
words
company
may
actually
achieve
plans
intentions
expectations
disclosed
statements
place
undue
reliance
statements
actual
results
events
could
differ
materially
plans
intentions
expectations
disclosed
statements
result
various
factors
including
uncertainties
inherent
litigation
including
patent
interference
proceedings
uncertainties
inherent
initiation
completion
studies
clinical
trials
clinical
development
company
product
candidates
availability
timing
results
studies
clinical
trials
whether
interim
results
clinical
trial
predictive
final
results
trial
results
future
trials
expectations
regulatory
approvals
conduct
trials
market
products
availability
funding
sufficient
company
foreseeable
unforeseeable
operating
expenses
capital
expenditure
requirements
risks
described
greater
detail
caption
risk
factors
included
company
recent
quarterly
report
form
file
securities
exchange
commission
filings
company
may
make
securities
exchange
commission
future
statements
contained
press
release
represent
company
views
date
hereof
relied
upon
representing
views
subsequent
date
except
required
law
company
explicitly
disclaims
obligation
update
statements
